Cover Image
市場調查報告書

中國的糖尿病市場分析:患者數、盛行率、口服抗糖尿病劑、胰島素、診斷藥

China Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics

出版商 IMARC Services Pvt. Ltd. 商品編碼 345918
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的糖尿病市場分析:患者數、盛行率、口服抗糖尿病劑、胰島素、診斷藥 China Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics
出版日期: 2015年11月26日 內容資訊: 英文
簡介

中國有全球最大的糖尿病患者人口,近幾年在成人之間發病數急速增加。約30年前,糖尿病患者不滿成人人口的1%,不過,現在擴大到約12%。其要素為迅速的經濟發展和都市化,飲食的變化 (脂肪、白米的消費量增加),認知度低,貧乏的醫療基礎設施,以坐著工作為中心的生活 (運動量低),還有中國人整體比西方人擁有容易患糖尿病的體質等。政府和醫療相關人員被要求緊急應變,另一方面,這樣的情形,對糖尿病的治療藥、診斷藥廠商來說也可說是出現巨大的市場機會。

本報告提供中國國內的糖尿病治療藥、診斷藥的市場相關分析、患病人數的轉變/預測和結構 (年齡、性別等)、市場的主要影響因素、治療藥、診斷藥的市場規模與今後的預測、今後市場機會等調查評估。

第1章 分析方法

第2章 摘要整理

第3章 糖尿病概要

  • 糖尿病為何?
  • 糖尿病的診斷和治療
    • 診斷法
    • 治療方法
  • 糖尿病的併發症

第4章 中國的糖尿病市場主要推動因素

第5章 中國國內的糖尿病的流行病學

  • 糖尿病的患者人口和盛行率
  • 糖尿病的患者人口和盛行率:各類型 (第一型、二型)
  • 糖尿病的患者人口和盛行率:各地區
  • 糖尿病的患者人口和盛行率:男女
  • 糖尿病的患者人口和盛行率:各年齡層
  • 糖尿病的診斷率、藥物治療率

第6章 中國的糖尿病市場

  • 到目前為止的市場趨勢 (過去8年份)
  • 各部門詳細趨勢 (過去8年份)
  • 中國的口服抗糖尿病劑的市場
    • 到目前為止的市場趨勢 (過去8年份)
    • 各級的市場區隔 (過去8年份)
    • 主要企業的市場佔有率
    • 市場未來展望 (今後6年份)
  • 中國的胰島素市場
  • 市場未來展望 (今後6年份)

第7章 中國的糖尿病診斷藥市場

  • 到目前為止的市場趨勢 (過去8年份)
  • 市場明細
  • 主要企業
  • 市場未來展望 (今後6年份)

圖表一覽

目錄
Product Code: SRP071534

China currently has the highest number of diabetics in the world. The disease has presently reached epidemic proportions in the adult population. Around three decades ago, less than one percent of the Chinese adult population had diabetes. These levels, however, have increased to around 12 percent - making it the diabetes capital of the world.

The rise of diabetes in China can be attributed to a number of factors. Driven by a strong economic growth over the past few decades, the Chinese population has become richer, fatter and less mobile. Apart from urbanisation and sedentary lifestyles, Chinese people are also genetically more vulnerable to diabetes compared to Europeans and many other population groups. Other factors such as poor awareness of health issues, high consumption of white rice, poor healthcare infrastructure, etc. have also driven the prevalence of the disease.

China's diabetes statistics may ring alarm bells for the government and healthcare authorities, for drug and diagnostic manufacturers, however, it represents a goldmine. Fuelled by a continuous increase in healthcare expenditures, the market for diabetes drugs and diagnostics is expanding robustly in the country. This is creating lucrative opportunities for global healthcare companies at a time when growth rates in the more developed markets have declined.

IMARC's new report "China Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics" provides an analytical and statistical insight into the Chinese diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in China. The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the Chinese diabetes market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the China diabetes market in any form.

What we have achieved in this report:

Comprehensive situation analysis of the Chinese diabetes epidemiology and its dynamics:

Focus of the Analysis:

  • Historical, current and future prevalence of diabetes in China
  • Historical, current and future prevalence of type-1 and type-2 diabetes in China
  • Historical, current and future prevalence of diabetes in the urban and rural regions in China
  • Historical, current and future prevalence of diabetes among males and females in China
  • Historical, current and future prevalence of diabetes among various age groups in China
  • Historical, current and future diagnosis rates for diabetes in China
  • Historical, current and future drug treatment rates for diabetes in China

Comprehensive situation analysis of the Chinese Oral Antidiabetics market and its dynamics:

Focus of the Analysis:

  • Performance of the Oral Antidiabetics market in China
  • Performance of key classes
  • Performance of key players
  • Market outlook

Comprehensive situation analysis of the Chinese Insulin market and its dynamics:

Focus of the Analysis:

  • Performance of the Insulin market in China
  • Performance of key classes
  • Performance of key players
  • Market outlook

Comprehensive situation analysis of the Chinese diabetes diagnostics market and its dynamics:

Focus of the Analysis:

  • Performance of the diabetes diagnostics market in China
  • Market Segmentation
  • Key players
  • Market outlook

Table of Contents

1 Research Methodology

2 Executive Summary

3 Diabetes Disease Overview

  • 3.1 What is Diabetes?
  • 3.2 Diabetes Diagnosis and Treatment
    • 3.2.1 Diagnosis
    • 3.2.2 Treatment
  • 3.3 Diabetes Complications

4 KeyFactors Driving the Diabetes Market in China

5 China Diabetes Epidemiology

  • 5.1 Diabetes Population and Prevalence Rates
  • 5.2 Population and Prevalence Rates by Diabetes Type (Type-1 and Type-2)
  • 5.3 Population and Prevalence Rates by Region
  • 5.4 Population and Prevalence Rates by Gender
  • 5.5 Population and Prevalence Rates by Age Group
  • 5.6 Diabetes Diagnosis and Drug Treatment Rates

6 China Diabetes Market

  • 6.1 Historical Market Trends (2007-2014)
  • 6.2 Market Breakup by Segment (2007-2014)
  • 6.3 China Oral Antidiabetics Market
    • 6.3.1 Historical Market Trends (2007-2014)
    • 6.3.2 Market Breakup by Class (2007-2014)
    • 6.3.3 Market Shares of Key Players
    • 6.3.4 Market Outlook (2015-2020)
  • 6.4 China Insulin Market
    • 6.4.1 Historical Market Trends (2015-2020)
    • 6.4.2 Market Breakup by Class
    • 6.4.3 Market Shares of Key Players
    • 6.4.4 Market Outlook (2015-2020)
  • 6.5 Market Outlook (2015-2020)

7 China Diabetes Diagnostics Market

  • 7.1 Historical Market Trends (2007-2014)
  • 7.2 Market Segmentation
  • 7.3 Key Players
  • 7.4 Market Outlook (2015-2020)

List of Figures

  • Figure 3 1: The Impact of Diabetes on the Human Body
  • Figure 3 2: Diabetes Complications
  • Figure 4 1: China: Overweight & Obese Population (in Millions), 2007, 2014 & 2020
  • Figure 4 2: Body Mass Index and Relative Risk of Type-2 Diabetes
  • Figure 4 3: Global: Breakup of Diabetes Patients by Region (in %), 2014 & 2030
  • Figure 5 1: China: Total Number of Diabetes Patients (in Millions), 2007- 2014
  • Figure 5 2: China: Total Number of Diabetes Patients (in Millions), 2015 - 2020
  • Figure 5 3: China (Type1 & Type2): Total Number of Diabetes Patients (in Millions), 2007- 2014
  • Figure 5 4: China (Type1 & Type2): Total Number of Diabetes Patients (in Millions) 2015 - 2020
  • Figure 5 5: China (Urban & Rural): Total Number of Diabetes Patients (in Millions), 2007- 2014
  • Figure 5 6: China (Urban & Rural): Total Number of Diabetes Patients (in Millions), 2015 - 2020
  • Figure 5 7: China (Male & Female): Total Number of Diabetes Patients (in Millions), 2007- 2014
  • Figure 5 8: China (Male & Female): Total Number of Diabetes Patients (in Millions), 2015 - 2020
  • Figure 5 9: China: Total Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (in Millions), 2007- 2014
  • Figure 5 10: China: Total Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (in Millions), 2015 - 2020
  • Figure 5 11: China: Total Diagnosed & Drug Treated Diabetes Population (in Millions), 2007- 2014
  • Figure 5 12:China: Total Diagnosed & Drug Treated Diabetes Population (in Millions), 2015 - 2020
  • Figure 6 1: China: Diabetes Market (in Million US$), 2007-2014
  • Figure 6 2: China: Diabetes Market: Share of Oral Antidiabetics and Insulin (in %), 2007-2014
  • Figure 6 3: China: Oral Antidiabetics Market (in Million US$), 2007-2014
  • Figure 6 4: China: Oral Antidiabetics Market: Sales Share of Key Classes (in %), 2007-2014
  • Figure 6 5: China: Oral Antidiabetics Market: Sales Share of Key Players (in %)
  • Figure 6 6: China: Oral Antidiabetics Market Forecast (in Million US$), 2015-2020
  • Figure 6 7: China: Oral Antidiabetics Market Forecast: Sales Share of Key Classes (in %), 2015 & 2020
  • Figure 6 8: China: Insulin Market (in Million US$), 2007-2014
  • Figure 6 9: China: Insulin Market: Sales Share of Key Classes (in %), 2014
  • Figure 6 10: China: Insulin Market: Sales Share of Key Players (in %)
  • Figure 6 11: China: Insulin Market Forecast (in Million US$), 2015-2020
  • Figure 6 12: China: Insulin Market Forecast: Sales Share of Key Classes (in %), 2015 & 2020
  • Figure 6 13: China: Diabetes Market Forecast (in Million US$), 2015-2020
  • Figure 6 14: China: Diabetes Market Forecast: Share of Oral Antidiabetics and Insulin (in %), 2015-2020
  • Figure 7 1: China: Diabetes Diagnostics Market (in Million US$), 2007-2014
  • Figure 7 2: China: Diabetes Diagnostics Market Forecast (in Million US$), 2015-2020

List of Tables

  • Table 2 1: China: Diabetes Epidemiology: Executive Summary
  • Table 2 2: China: Diabetes Market: Executive Summary
  • Table 3 1: Diagnosis of Diabetes
  • Table 4 1: China: Overweight & Obesity Statistics, 2006, 2010 & 2014
  • Table 4 2: China: Urban & Rural Population Breakup (in Millions), 1991, 2001, 2011 & 2014
  • Table 4 3: Global: Diabetes Population Breakup by Country (in 000's), 2014 & 2020
  • Table 4 4: Global: Market Size & Growth Rates of Top Emerging and Developed Diabetes Drug Markets
  • Table 5 1: China: Total Prevalence & Number of Diabetes Patients, 2007, 2014 & 2020
  • Table 5 2: China (Type1 & Type2): Total Prevalence & Number of Diabetes Patients, 2007, 2014 & 2020
  • Table 5 3: China (Urban & Rural): Total Prevalence & Number of Diabetes Patients, 2007, 2014 & 2020
  • Table 5 4: China (Male & Female): Total Prevalence & Number of Diabetes Patients, 2007, 2014 & 2020
  • Table 5 5: Total Prevalence & Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (In Millions), 2007, 2014 & 2020
  • Table 5 6: China: Total Diagnosed & Drug Treated Diabetes Population, 2007, 2014 & 2020
Back to Top